Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY:MRK)

89.34 +0.11 (+0.12%)
Streaming Delayed Price Updated: 2:16 PM EDT, Mar 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 6,370,404
Open 89.25
Bid (Size) 89.34 (2)
Ask (Size) 89.35 (2)
Prev. Close 89.23
Today's Range 88.37 - 89.95
52wk Range 81.04 - 134.63
Shares Outstanding 2,531,374,696
Dividend Yield 3.45%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Does AstraZeneca Have 'One Pill To Rule Them All' In Cholesterol?
The company unveiled promising results for its experimental cholesterol treatment, a daily pill that blocks PCSK9. 
Via Investor's Business Daily
WINREVAIR™ (sotatercept-csrk) Reduced the Risk of a Composite of All-Cause Death, Lung Transplantation and Hospitalization for Pulmonary Arterial Hypertension (PAH) by 76% Compared to Placebo in the Phase 3 ZENITH Trial
From Merck Sharp & Dohme
Via Business Wire

Performance

YTD
-9.9%
-9.9%
1 Month
-3.2%
-3.2%
3 Month
-9.2%
-9.2%
6 Month
-21.3%
-21.3%
1 Year
-31.8%
-31.8%

More News

Read More
Want $1 Million in Retirement? 3 Stocks to Buy Now and Hold for Decades.
Via The Motley Fool
Topics Intellectual Property Retirement
Exposures Intellectual Property Pension
ROSEN, LEADING INVESTOR COUNSEL, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – MRK
From The Rosen Law Firm PA
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Merck & Co., Inc. of Class Action Lawsuit and Upcoming Deadlines – MRK
From Pomerantz LLP
Via GlobeNewswire
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Merck & Co.
From Faruqi & Faruqi LLP
Via GlobeNewswire
What's going on in today's session: S&P500 movers
Via Chartmill
Which S&P500 stocks are moving on Friday?
Via Chartmill
Which Dow Jones Stock Is Cheaper, Amgen or Merck?
Via The Motley Fool
Topics Intellectual Property Stocks
Exposures Intellectual Property US Equities
ROSEN, LEADING TRIAL ATTORNEYS, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – MRK
From The Rosen Law Firm PA
Via GlobeNewswire
Merck’s Investigational Subcutaneous Pembrolizumab With Berahyaluronidase Alfa Demonstrates Noninferior Pharmacokinetics Compared to Intravenous (IV) KEYTRUDA® (pembrolizumab) in Pivotal 3475A-D77 Trial
From Merck & Co., Inc.
Via Business Wire
Merck's Biggest Moneymaker Could Get Even Bigger. But Will It Help Downtrodden Shares?
Via Investor's Business Daily
Exposures Product Safety
Is Merck Stock a Bargain Buy?
Via The Motley Fool
Faruqi & Faruqi Reminds Merck Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 14, 2025 - MRK
From Faruqi & Faruqi LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Merck & Co., Inc. of Class Action Lawsuit and Upcoming Deadlines – MRK
From Pomerantz LLP
Via GlobeNewswire
European Commission (EC) Approves Merck’s CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) for Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in Adults
From Merck & Co., Inc.
Via Business Wire
Gamestop, FST Corp, Merck, UPS, And Tesla: Why These 5 Stocks Are On Investors' Radars Today
Via Benzinga
Topics Stocks
Exposures US Equities
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against FMC, TransMedics, Alarum, and Merck and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Why Pharma and Biotech Stocks Got Thrashed on Tuesday
Via The Motley Fool
What's going on in today's session: S&P500 movers
Via Chartmill
Tuesday's session: top gainers and losers in the S&P500 index
Via Chartmill
Merck Enters $2B License Agreement With China-Based Hengrui Pharma For Heart Disease Drug: Retail’s Unswayed
Via Stocktwits
Merck Partners With Hengrui Pharma In $1.77 Billion Deal For Cardiovascular Treatment
Via Benzinga
Mural Oncology's Ovarian Cancer Combo Drug Trial Disappoints, Stock Plunges
Via Benzinga
Merck Enters Exclusive License Agreement for HRS-5346, an Investigational Oral Lipoprotein(a) Inhibitor, for Cardiovascular Disease from Jiangsu Hengrui Pharmaceuticals Co., Ltd.
From Merck & Co., Inc.
Via Business Wire

Frequently Asked Questions

Is Merck & Co publicly traded?
Yes, Merck & Co is publicly traded.
What exchange does Merck & Co trade on?
Merck & Co trades on the New York Stock Exchange
What is the ticker symbol for Merck & Co?
The ticker symbol for Merck & Co is MRK on the New York Stock Exchange
What is the current price of Merck & Co?
The current price of Merck & Co is 89.34
When was Merck & Co last traded?
The last trade of Merck & Co was at 03/31/25 02:16 PM ET
What is the market capitalization of Merck & Co?
The market capitalization of Merck & Co is 226.15B
How many shares of Merck & Co are outstanding?
Merck & Co has 226B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.